1. Home
  2. RUN vs NAMS Comparison

RUN vs NAMS Comparison

Compare RUN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrun Inc.

RUN

Sunrun Inc.

HOLD

Current Price

$13.44

Market Cap

3.3B

Sector

Miscellaneous

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.57

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUN
NAMS
Founded
2007
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.5B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
RUN
NAMS
Price
$13.44
$34.57
Analyst Decision
Buy
Strong Buy
Analyst Count
20
8
Target Price
$19.10
$46.75
AVG Volume (30 Days)
7.1M
794.4K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
113.35
N/A
EPS
1.71
N/A
Revenue
$858,578,000.00
N/A
Revenue This Year
$1.08
$17.96
Revenue Next Year
$4.42
$540.65
P/E Ratio
$7.79
N/A
Revenue Growth
12.97
N/A
52 Week Low
$5.38
$14.92
52 Week High
$22.44
$42.00

Technical Indicators

Market Signals
Indicator
RUN
NAMS
Relative Strength Index (RSI) 48.13 61.05
Support Level $12.01 $34.05
Resistance Level $13.57 $37.43
Average True Range (ATR) 0.72 1.69
MACD 0.27 0.58
Stochastic Oscillator 52.24 88.69

Price Performance

Historical Comparison
RUN
NAMS

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: